Viridian Therapeutics, Inc. (VRDN)
Viridian Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Waltham, MA, US. The stock last traded at $23.28, up 1.35% on the session, giving a market capitalisation of $2.64B. On trailing twelve-month figures it carries a trailing P/E of -6.36, a net margin of -544.1%. Its beta of 0.94 implies it has historically moved less than the broad market.
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
Viridian Therapeutics, Inc. is most often compared with the following Healthcare names: